Home
Search:
1146 feeds
357 categories
6188 articles (<24 hours)
15 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

Science


Valid HTML 4.01 Transitional

RSS FeedsHIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019
(WorldNews Health)

 
 

11 november 2019 04:20:53

 
HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019
(WorldNews Health)
 




November 11, 2019 HIF-PH Inhibitor Vadadustat (MT-6548) Japan Phase 3 results for the treatment of renal anemia at American Society of Nephrology, Kidney Week 2019 Mitsubishi Tanabe Pharma Corporation (MTPC, Head Office: Chuo-ku, Osaka; President & Representative Director: Masayuki Mitsuka, Ph.D.) today announced that Phase 3 results of Vadadustat (MT-6548) in Japan have been presented at American Society of Nephrology (ASN) Kidney Week 2019 from November 5 to November 10, 2019 in Washington DC. MTPC has submitted to the Ministry of Health, Labour and Welfare in Japan an application for the manufacturing and marketing approval of Vadadustat (MT-6548) on July 2019.
 
21 viewsCategory: Science > Medicine
 
Mitsubishi Tanabe Pharma Corporation Announces Results of the MT-7117 ENDEAVOR Study for the Ultra-Rare Disease, Erythropoietic Protoporphyria (EPP)
(WorldNews Health)
Online video shows Hong Kong police shoot at least one protester as demonstrators disrupt morning...
(WorldNews Health)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2019 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Travel Photos Nachrichten Indigonet Finances Leer Mandarijn